Testing new treatment for Hodgkin lymphoma that came back
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a treatment plan for adults with Hodgkin lymphoma that has returned or did not respond to ABVD chemotherapy. It may help people with a higher-risk pattern of disease, as long as their organ function and overall health meet study limits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 90
- Your Hodgkin lymphoma has relapsed or is refractory to ABVD, and is considered high risk
- Your liver blood tests are within limits (bilirubin, AST, and ALT)
- Your kidney function is within limits (creatinine or kidney filtration rate)
- Your overall health status is fair enough for treatment (ECOG 0 to 3)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well brentuximab vedotin works for adults with Hodgkin’s lymphoma who have either already had, or are being considered for, stem cell transplant. It may help people who are receiving a specific treatment plan to control the lymphoma after transplant planning.
This trial tests a combination of the targeted drug brentuximab vedotin with standard chemotherapy (doxorubicin, vinblastine, and dacarbazine) for adults with Stage 3 or 4 Hodgkin lymphoma who have not had previous treatment. It aims to see if this combination works well and is safe.
This trial tests a combination of two drugs (brentuximab vedotin, AVD chemotherapy) for people with newly diagnosed, bulky Hodgkin lymphoma that hasn't spread far. It aims to see if this treatment works well for larger tumors.
This Phase 3 trial studies whether adding brentuximab vedotin to standard chemotherapy improves outcomes for people with newly diagnosed early-stage classical Hodgkin lymphoma. It may help reduce the chance the cancer returns or improves how well treatment works.
This trial is a survey study that looks at how brentuximab vedotin is used in children with Hodgkin lymphoma. It focuses on people whose tumor is CD30-positive and who have not had prior treatment, to see how the drug fits with a standard chemotherapy plan (AVD).
This trial tests a combination drug treatment called BrECADD for people with Hodgkin lymphoma that has certain risk factors or is in a more advanced stage (stage 2B, 3, or 4). It aims to see if this treatment works well and is safe.
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.